Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis

Anoop Titus; Huzaifa Ahmad Cheema; Arman Shafiee; Niloofar Seighali; Abia Shahid; Karan B. Bhanushali; Ashish Kumar; Safi U. Khan; Sumanth Khadke; Paaladinesh Thavendiranathan; W. Gregory Hundley; Marielle Scherrer-Crosbie; Anju Nohria; Tomas G. Neilan; Sourbha S. Dani; Khurram Nasir; Sarju Ganatra

doi:10.1016/j.cpcardiol.2023.101885

Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis

Anoop Titus, Huzaifa Ahmad Cheema, Arman Shafiee, Niloofar Seighali, Abia Shahid, Karan B. Bhanushali, Ashish Kumar, Safi U. Khan, Sumanth Khadke, Paaladinesh Thavendiranathan, W. Gregory Hundley, Marielle Scherrer-Crosbie, Anju Nohria, Tomas G. Neilan, Sourbha S. Dani, Khurram Nasir, Sarju Ganatra

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of studies using statins and anthracyclines by searching PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception until April 10, 2023. Our analysis included 3 observational studies and 4 RCTs, including the STOP-CA trial released in ACC23. Statin prescription significantly reduced cardiotoxicity in cancer patients receiving anthracycline chemotherapy (OR 0.46, 95% CI: 0.33-0.63; I2: 0%). However, no significant difference was observed in the decline of left ventricular ejection fraction (LVEF) from baseline (MD 4.15, 95% CI: -0.69 to 8.99, I2: 97%). These findings demonstrate the protective effect of concomitant statin prescription.

Original language	English (US)
Article number	101885
Pages (from-to)	101885
Journal	Current Problems in Cardiology
Volume	48
Issue number	10
Early online date	Jun 17 2023
DOIs	https://doi.org/10.1016/j.cpcardiol.2023.101885
State	Published - Oct 2023

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.cpcardiol.2023.101885

Cite this

Titus, A., Cheema, H. A., Shafiee, A., Seighali, N., Shahid, A., Bhanushali, K. B., Kumar, A., Khan, S. U., Khadke, S., Thavendiranathan, P., Hundley, W. G., Scherrer-Crosbie, M., Nohria, A., Neilan, T. G., Dani, S. S., Nasir, K., & Ganatra, S. (2023). Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis. Current Problems in Cardiology, 48(10), 101885. Article 101885. https://doi.org/10.1016/j.cpcardiol.2023.101885

Titus, A, Cheema, HA, Shafiee, A, Seighali, N, Shahid, A, Bhanushali, KB, Kumar, A, Khan, SU, Khadke, S, Thavendiranathan, P, Hundley, WG, Scherrer-Crosbie, M, Nohria, A, Neilan, TG, Dani, SS, Nasir, K & Ganatra, S 2023, 'Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis', Current Problems in Cardiology, vol. 48, no. 10, 101885, pp. 101885. https://doi.org/10.1016/j.cpcardiol.2023.101885

@article{e5af42a92e0c4778b4d16aea5cca9c2b,

title = "Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis",

abstract = "Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of studies using statins and anthracyclines by searching PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception until April 10, 2023. Our analysis included 3 observational studies and 4 RCTs, including the STOP-CA trial released in ACC23. Statin prescription significantly reduced cardiotoxicity in cancer patients receiving anthracycline chemotherapy (OR 0.46, 95\% CI: 0.33-0.63; I2: 0\%). However, no significant difference was observed in the decline of left ventricular ejection fraction (LVEF) from baseline (MD 4.15, 95\% CI: -0.69 to 8.99, I2: 97\%). These findings demonstrate the protective effect of concomitant statin prescription.",

author = "Anoop Titus and Cheema, \{Huzaifa Ahmad\} and Arman Shafiee and Niloofar Seighali and Abia Shahid and Bhanushali, \{Karan B.\} and Ashish Kumar and Khan, \{Safi U.\} and Sumanth Khadke and Paaladinesh Thavendiranathan and Hundley, \{W. Gregory\} and Marielle Scherrer-Crosbie and Anju Nohria and Neilan, \{Tomas G.\} and Dani, \{Sourbha S.\} and Khurram Nasir and Sarju Ganatra",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = oct,

doi = "10.1016/j.cpcardiol.2023.101885",

language = "English (US)",

volume = "48",

pages = "101885",

journal = "Current Problems in Cardiology",

issn = "0146-2806",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines

T2 - A Systematic Review and Meta-Analysis

AU - Titus, Anoop

AU - Cheema, Huzaifa Ahmad

AU - Shafiee, Arman

AU - Seighali, Niloofar

AU - Shahid, Abia

AU - Bhanushali, Karan B.

AU - Kumar, Ashish

AU - Khan, Safi U.

AU - Khadke, Sumanth

AU - Thavendiranathan, Paaladinesh

AU - Hundley, W. Gregory

AU - Scherrer-Crosbie, Marielle

AU - Nohria, Anju

AU - Neilan, Tomas G.

AU - Dani, Sourbha S.

AU - Nasir, Khurram

AU - Ganatra, Sarju

PY - 2023/10

Y1 - 2023/10

N2 - Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of studies using statins and anthracyclines by searching PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception until April 10, 2023. Our analysis included 3 observational studies and 4 RCTs, including the STOP-CA trial released in ACC23. Statin prescription significantly reduced cardiotoxicity in cancer patients receiving anthracycline chemotherapy (OR 0.46, 95% CI: 0.33-0.63; I2: 0%). However, no significant difference was observed in the decline of left ventricular ejection fraction (LVEF) from baseline (MD 4.15, 95% CI: -0.69 to 8.99, I2: 97%). These findings demonstrate the protective effect of concomitant statin prescription.

AB - Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of studies using statins and anthracyclines by searching PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception until April 10, 2023. Our analysis included 3 observational studies and 4 RCTs, including the STOP-CA trial released in ACC23. Statin prescription significantly reduced cardiotoxicity in cancer patients receiving anthracycline chemotherapy (OR 0.46, 95% CI: 0.33-0.63; I2: 0%). However, no significant difference was observed in the decline of left ventricular ejection fraction (LVEF) from baseline (MD 4.15, 95% CI: -0.69 to 8.99, I2: 97%). These findings demonstrate the protective effect of concomitant statin prescription.

UR - https://www.scopus.com/pages/publications/85164336037

UR - https://www.scopus.com/inward/citedby.url?scp=85164336037&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2023.101885

DO - 10.1016/j.cpcardiol.2023.101885

M3 - Review article

C2 - 37336312

AN - SCOPUS:85164336037

SN - 0146-2806

VL - 48

SP - 101885

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

IS - 10

M1 - 101885

ER -

Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this